Insight
Understanding Gastrointestinal Toxicity Risk Through Human Relevant Intestinal Models
Translational safety insights help differentiate risk and support more informed development decisions.
Gastrointestinal toxicity remains a major challenge for targeted therapies, often impacting dose optimization and patient tolerability. See how iPSC-derived intestinal organoids, high-content imaging, and PBPK modeling were used to differentiate GI toxicity risk across EGFR inhibitors and generate translational insights to support safer development decisions.
Download Document
Related Insights
Specifica Antibody Discovery Campaigns
Specifica Library Platform Transfer
Specifica Affinity Maturation & Developability Optimization
Discovery Sciences – Innovative Antibody Drug Discovery Services
Immunogenicity Assessment and Functional Testing of Candidate Therapeutics
Presented by Chloe Ackaert, PhD at AAPS PharmSci360 in 2023
Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis
Unleashing the power of MHC Associated Peptide Proteomics: Immunogenicity Assessment of Oncology Drugs
In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays
Monoclonal Antibodies Reagents
